T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity

Antibody response to the first dose of BNT162b2 SARS-CoV-2 is greater in COVID-19-convalescent than in infection-naïve individuals. However, there are no data about T-cell response in individuals with pre-existing cellular immunity. We evaluated T-cell responses in parallel with SARS-CoV-2 antibody...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical & translational immunology Vol. 10; no. 9; p. e1341
Main Authors:	Casado, Jose L, Haemmerle, Johannes, Vizcarra, Pilar, Rodriguez-Dominguez, Mario, Velasco, Tamara, Velasco, Hector, Centenera, Elena, Romero-Hernandez, Beatriz, Fernandez-Escribano, Marina, Vallejo, Alejandro
Format:	Journal Article
Language:	English
Published:	Australia John Wiley & Sons, Inc 01-01-2021 John Wiley and Sons Inc Wiley
Subjects:	Antibodies Antibody response Cell-mediated immunity cellular immunity Coronaviruses COVID-19 COVID-19 vaccines cross‐reactivity Humoral immunity Immunoglobulin G Infections Lymphocytes Lymphocytes T Medical personnel mRNA vaccine mRNA vaccines Nucleocapsids Peptides Proteins SARS‐CoV‐2 Serology Severe acute respiratory syndrome coronavirus 2 Short Communication Vaccination Vaccines antibodies COVID‐19 SARS‐CoV‐2 cellular immunity cross‐reactivity mRNA vaccine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!